Hydroxyurea use in sickle cell disease: The battle with low prescription rates, poor patient compliance and fears of toxicities

Expert Review of Hematology

Volumn 3, Issue 3, 2010, Pages 255-260

  Brandow, Amanda M ^a   Panepinto, Julie A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; KETOROLAC; OPIATE;

ANEMIA; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; EDITORIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERPIGMENTATION; LEUKEMIA; MALE FERTILITY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; THROMBOCYTOPENIA;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; DRUG MONITORING; FEAR; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; MALE; PATIENT COMPLIANCE; PATIENT FREEDOM OF CHOICE LAWS; RISK ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953494025     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.10.22     Document Type: Editorial

References (52)

1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am. J. Hematol. 85, 77-78 (2010).
2. Hoffmann RG. Hematology: Basic Principles and Practice (4th Edition). Elsevier Churchill Livingstone, PA, USA (2005).
3. Platt OS, Thorington BD, Brambilla DJ et al. Pain in sickle cell disease. Rates and risk factors. N. Engl. J. Med. 325, 11-16 (1991).
4. Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639-1644 (1994).
5. Smith WR, Penberthy LT, Bovbjerg VE et al. Daily assessment of pain in adults with sickle cell disease. Ann. Intern. Med. 148, 94-101 (2008).
6. Dampier C, Ely E, Brodecki D, O'Neal P. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J. Pediatr. Hematol. Oncol. 24, 643-647 (2002).
7. Wang WC. Pain at home in sickle cell disease: an underrecognized problem. J. Pediatric Hematol. Oncol. 24, 610-612 (2002).
8. Walco GA, Dampier CD. Pain in children and adolescents with sickle cell disease: a descriptive study. J. Pediatr. Psychol. 15, 643-658 (1990).
9. Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br. J. Haematol. 144, 782-788 (2009).
10. Panepinto JA, Brousseau DC, Hillery CA, Scott JP. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr. Blood Cancer 44, 182-186 (2005).
11. Iannone R, Ohene-Frempong K, Fuchs EJ, Casella JF, Chen AR. Bone marrow transplantation for sickle cell anemia: progress and prospects. Pediatr. Blood Cancer 44, 436-440 (2005).
12. Steinberg MH, Barton F, Castro O et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289, 1645-1651 (2003).
13. Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N. Engl. J. Med. 332, 1317-1322 (1995).
14. DeSimone J, Koshy M, Dorn L et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99, 3905-3908 (2002).
15. Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea therapy in children severely affected with sickle cell disease. J. Pediatrics 128, 820-828 (1996).
16. Jayabose S, Tugal O, Sandoval C et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J. Pediatrics 129, 559-565 (1996).
17. Ferster A, Vermylen C, Cornu G et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 88, 1960-1964 (1996).
18. Zimmerman SA, Schultz WH, Davis JS et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103, 2039-2045 (2004).
19. Hankins JS, Ware RE, Rogers ZR et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106, 2269-2275 (2005).
20. Kinney TR, Helms RW, O'Branski EE et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a Phase I/II trial. Pediatric Hydroxyurea Group. Blood 94, 1550-1554 (1999).
21. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Pediatr. Clin. North Am. 55, 483-501 (2008).
22. NIH. The Management of Sickle Cell Disease. NIH, MD, USA 161-165 (2002).
23. Ballas SK, Lieff S, Benjamin LJ et al. Definitions of the phenotypic manifestations of sickle cell disease. Am. J. Hematol. 85, 6-13 (2009).
24. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am. J. Hematol. 79, 17-25 (2005).
25. Frei-Jones MJ, Field JJ, DeBaun MR. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr. Blood Cancer 52, 481-485 (2009).
26. Brandow AM, Jirovec, DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Blood (ASH Annual Meeting Abstracts) 114, 242 (2009).
27. Panepinto JA, O'Mahar KM, DeBaun MR, Loberiza FR, Scott JP. Health-related quality of life in children with sickle cell disease: child and parent perception. Br. J. Haematol. 130, 437-444 (2005).
28. Brawley OW, Cornelius LJ, Edwards LR et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann. Intern. Med. 148, 932-938 (2008).
29. Osegbe DN, Akinyanju O, Amaku EO. Fertility in males with sickle cell disease. Lancet 2, 275-276(1981).
30. Agbaraji VO, Scott RB, Leto S, Kingslow LW. Fertility studies in sickle cell disease: semen analysis in adult male patients. Int. J. Fertil. 33, 347-352 (1988).
31. Modebe O, Ezeh UO. Effect of age on testicular function in adult males with sickle cell anemia. Fertil. Steril. 63, 907-912 (1995).
32. Berthaut I, Guignedoux G, Kirsch-Noir F et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 93, 988-993 (2008).
33. Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends Pharmacol. Sci. 30, 503-508 (2009).
34. Zumberg MS, Reddy S, Boyette RL, Schwartz RJ, Konrad TR, Lottenberg R. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/ oncologists. Am. J. Hematol. 79, 107-113 (2005).
35. Lanzkron S, Haywood C, Jr., Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J. Natl. Med. Assoc. 100, 968-973 (2008).
36. Lanzkron S, Haywood C Jr, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am. J. Hematol. 81, 927-932 (2006).
37. Brawley OW, Cornelius LJ, Edwards LR et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann. Intern. Med. 148, 932-938 (2008).
38. Lanzkron S, Haywood C Jr, Fagan PJ, Rand CS. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J. Health Care Poor Underserved 21, 277-286 (2010).
39. Hankins J, Hinds P, Day S et al. Therapy preference and decision-making among patients with severe sickle cell anemia and their families. Pediatr. Blood Cancer 48, 705-710 (2007).
40. Haywood C Jr, Beach MC, Lanzkron S et al. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J. Natl Med. Assoc. 101, 1022-1033 (2009).
41. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J. Pediatr. 156, 415-419 (2010).
42. Barbarin OA Whitten CF, Bond S, Conner-Warren R. The social and cultural context of coping with sickle cell disease: III. Stress, coping tasks, family functioning, and children's adjustment. J. Black Psychology 25, 356-377 (1999).
43. Hill S. Managing Sickle Cell Disease in Low-Income Families. Temple University Press, PA, USA (1994).
44. Raphael JL, Dietrich CL, Whitmire D et al. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatric Blood Cancer 52, 263-267 (2009).
45. Raphael JL, Guadagnolo BA, Beal AC, Giardino AP. Racial and ethnic disparities in indicators of a primary care medical home for children. Acad. Pediatr. 9, 221-227 (2009).
46. Alegria M, Chatterji P, Wells K et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr. Serv. 59, 1264-1272 (2008).
47. Baquet CR, Mishra SI, Commiskey P, Ellison GL, DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J. Natl Med. Assoc. 100, 480-488 (2008).
48. Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J. Pain 10, 1187-1204 (2009).
49. Ballas SK, Barton FB, Waclawiw MA et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual. Life Outcomes 4, 59 (2006).
50. Ferster A, Tahriri P, Vermylen C et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97, 3628-3632 (2001).
51. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J. Pediatrics 139, 790-796 (2001).
52. Ballas SK, McCarthy WF, Guo N et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J. Natl Med. Assoc. 101, 1046-1051 (2009)